日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

NRX-0492 可降解野生型和 C481 突变型 BTK,并在 CLL 患者来源的异种移植模型中显示出体内活性。

Deyi Zhang ,Hailey M Harris ,Jonathan Chen ,Jen Judy ,Gabriella James ,Aileen Kelly ,Joel McIntosh ,Austin Tenn-McClellan ,Eileen Ambing ,Ying Siow Tan ,Hao Lu ,Stefan Gajewski ,Matthew C Clifton ,Stephanie Yung ,Daniel W Robbins ,Mehdi Pirooznia ,Sigrid S Skånland ,Erika Gaglione ,Maissa Mhibik ,Chingiz Underbayev ,Inhye E Ahn ,Clare Sun ,Sarah E M Herman ,Mark Noviski ,Adrian Wiestner

Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL

增强的共刺激信号可改善慢性淋巴细胞白血病中 CAR T 细胞的效应反应

McKensie A Collins ,In-Young Jung ,Ziran Zhao ,Kimberly Apodaca ,Weimin Kong ,Stefan Lundh ,Joseph A Fraietta ,Arnon P Kater ,Clare Sun ,Adrian Wiestner ,J Joseph Melenhorst

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

BTK 抑制剂(无论 ITK 抑制与否)可增强 CD19/CD3 双特异性抗体在 CLL 中的疗效

Maissa Mhibik, Erika M Gaglione, David Eik, Ellen K Kendall, Amy Blackburn, Keyvan Keyvanfar, Maria Joao Baptista, Inhye E Ahn, Clare Sun, Junpeng Qi, Christoph Rader, Adrian Wiestner

MARCKS affects cell motility and response to BTK inhibitors in CLL

MARCKS 影响 CLL 中的细胞迁移和对 BTK 抑制剂的反应

Laura Beckmann, Valeska Berg, Clarissa Dickhut, Clare Sun, Olaf Merkel, Johannes Bloehdorn, Sandra Robrecht, Marc Seifert, Alexandra da Palma Guerreiro, Julia Claasen, Stefan Loroch, Matteo Oliverio, Chingiz Underbayev, Lauren Vaughn, Daniel Thomalla, Malte F Hülsemann, Eugen Tausch, Kirsten Fischer

Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

接受伊布替尼治疗的慢性淋巴细胞白血病患者中选择性抗肿瘤细胞毒性 CD8+ T 细胞克隆型扩增

Maria Joao Baptista, Sivasubramanian Baskar, Erika M Gaglione, Keyvan Keyvanfar, Inhye E Ahn, Adrian Wiestner, Clare Sun

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

BTK 抑制剂阿卡替尼治疗慢性淋巴细胞白血病 (CLL) 的靶标占据率的临床和生物学意义

Clare Sun, Pia Nierman, Ellen K Kendall, Jean Cheung, Michael Gulrajani, Sarah E M Herman, Christopher Pleyer, Inhye E Ahn, Maryalice Stetler-Stevenson, Constance M Yuan, Irina Maric, Erika M Gaglione, Hailey M Harris, Stefania Pittaluga, Min Hui Wang, Priti Patel, Mohammed Z H Farooqui, Raquel Izum

Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

BTK 抑制对接受 Acalabrutinib 治疗的慢性淋巴细胞白血病患者的药效学分析

Anfal Alsadhan, Jean Cheung, Michael Gulrajani, Erika M Gaglione, Pia Nierman, Ahmed Hamdy, Raquel Izumi, Elena Bibikova, Priti Patel, Clare Sun, Todd Covey #, Sarah E M Herman #, Adrian Wiestner #

Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia

肿瘤微环境中 Th1 免疫的激活与慢性淋巴细胞白血病对来那度胺的临床反应相关

Georg Aue, Clare Sun, Delong Liu, Jae-Hyun Park, Stefania Pittaluga, Xin Tian, Elinor Lee, Susan Soto, Janet Valdez, Irina Maric, Maryalice Stetler-Stevenson, Constance Yuan, Yusuke Nakamura, Pawel Muranski, Adrian Wiestner

Dicentric Dose Estimates for Patients Undergoing Radiotherapy in the RTGene Study to Assess Blood Dosimetric Models and the New Bayesian Method for Gradient Exposure

RTGene 研究中接受放射治疗患者的双着丝粒剂量估算,以评估血液剂量学模型和梯度暴露的新贝叶斯方法

Moquet, Jayne; Higueras, Manuel; Donovan, Ellen; Boyle, Sue; Barnard, Stephen; Bricknell, Clare; Sun, Mingzhu; Gothard, Lone; O'Brien, Grainne; Cruz-Garcia, Lourdes; Badie, Christophe; Ainsbury, Elizabeth; Somaiah, Navita

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

直接体内证据表明,与骨髓和外周血相比,淋巴结中的 CLL 细胞增殖增加

Thomas M Herndon #, Shih-Shih Chen #, Nakhle S Saba, Janet Valdez, Claire Emson, Michelle Gatmaitan, Xin Tian, Thomas E Hughes, Clare Sun, Diane C Arthur, Maryalice Stetler-Stevenson, Constance M Yuan, Carsten U Niemann, Gerald E Marti, Georg Aue, Susan Soto, Mohammed Z H Farooqui, Sarah E M Herman,